Kimberly Drenser, MD
Retina Specialist · Royal Oak, MINPI 1508894643
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $69,345 of the $78,716 with a category attached, or 88.1%. 15 manufacturers reported payments, led by Alcon at 42.6% of the total. Reporting peaked in 2019 at $33,503 and has fallen 54.9% since, to $15,121 in 2025. Among retina specialist clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $600.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$34K
- Regeneron$22K
- AbbVie$20K
- Alimera Sciences, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$925
- Genentech USA, Inc.$293
- plus $793 from 9 others
Across 17 payments — averaging $690.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$7K
- Regeneron$4K
- Spark Therapeutics, Inc.$813
What the payments were for
- Consulting fees$69,34588%
- Travel & lodging$4,1415%
- Food & beverage$5,2307%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 10 | $33,524 |
| Regeneron | 9 | $21,545 |
| AbbVie(2 entities) | 48 | $20,209 |
| Alimera Sciences, Inc. | 6 | $1,426 |
| Regeneron Healthcare Solutions, Inc. | 28 | $925 |
| Genentech USA, Inc. | 13 | $293 |
| Astellas Pharma US Inc | 6 | $200 |
| Johnson & Johnson | 2 | $156 |
| Coherus Oncology, Inc. | 1 | $130 |
| Oculus Surgical Inc. | 1 | $113 |
| Thrombogenics, Inc. | 1 | $77 |
| Novartis | 3 | $49 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Bausch & Lomb Americas Inc. | 1 | $21 |
| Ocular Therapeutix, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$78,716 in reported general payments places this provider in the 90th percentile of 52 retina specialist providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketorolac Tromethamine | 46 | $1,497 |
| Prednisolone Acetate | 31 | $1,425 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Royal Oak
- Jeremy WolfeRoyal Oak$809K
- Lisa FaiaRoyal Oak$520K
- Tarek HassanRoyal Oak$460K
- Sandeep RandhawaRoyal Oak$94K
- Adam WeinerRoyal Oak$31K
- Michael TreseRoyal Oak$26K
- Antonio CaponeRoyal Oak$20K
- Ramon LeeRoyal Oak$19K
- Jong ParkRoyal Oak$12K
- Tianyu LiuRoyal Oak$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.